Regeneron Pharmaceuticals (NasdaqGS:REGN) is poised for an eventful month, highlighting exciting advancements in their cancer and respiratory disease treatments at upcoming conferences. Following a ...

Truist lowered the firm’s price target on Regeneron (REGN) to $940 from $975 but keeps a Buy rating on the shares. The firm ...

Robert Radick writes his first health care enforcement roundup column for the NYLJ. "This new column will, every two months, ...

Seven months after the FDA approved the reintroduction of Roche's eye implant Susvimo, the US agency has expanded its approved use to include treatment for diabetic macular edema, the primary ...

Diabetic macular edema is a complication that develops from diabetic retinopathy, a widespread consequence of diabetes and a ...

Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release ...

Regeneron can’t dodge a lawsuit alleging it unlawfully inflated Medicare reimbursements for its eye drug Eylea and defrauded ...

Currently, EYLEA HD is approved for dosing intervals of 8-16 weeks for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). For patients with diabetic ...

Starting in 2025, the Eylea franchise as a whole began to decline due to competitive pressure from long-acting Vabysmo, which competes with Eylea HD, and Pabvlu, a biosimilar version of the original ...

Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

The S&P 500 advanced 0.6% on Tuesday, April 29, notching a sixth straight winning session. The White House signaled it would ...

Regeneron boosts antibody profits with higher Dupixent sales and expands biologics production via FUJIFILM Diosynth ...